首页> 外文期刊>Diabetes >Hydrogen Sulfide Induces Keap1 S-sulfhydration and Suppresses Diabetes-Accelerated Atherosclerosis via Nrf2 Activation
【24h】

Hydrogen Sulfide Induces Keap1 S-sulfhydration and Suppresses Diabetes-Accelerated Atherosclerosis via Nrf2 Activation

机译:硫化氢诱导Keap1 S硫酸化并通过Nrf2激活抑制糖尿病促进的动脉粥样硬化。

获取原文
获取原文并翻译 | 示例
       

摘要

Hydrogen sulfide (H_2S) has been shown to have powerful antioxidative and anti-inflammatory properties that can regulate multiple cardiovascular functions. However, its precise role in diabetes-accelerated atherosclerosis remains unclear. We report here that H_2S reduced aortic atherosclerotic plaque formation with reduction in super-oxide (O_2~-) generation and the adhesion molecules in streptozotocin (STZ)-induced LDLr~(-/-) mice but not in LDLr~(-/-)Nrf2~(-/-) mice. In vitro, H_2S inhibited foam cell formation, decreased O_2~- generation, and increased nuclear factor erythroid 2-related factor 2 (Nrf2) nuclear translo-cation and consequently heme oxygenase 1 (HO-1) expression upregulation in high glucose (HG) plus oxidized LDL (ox-LDL)-treated primary peritoneal macrophages from wild-type but not Nrf2~(-/-) mice. H_2S also decreased O_2~- and adhesion molecule levels and increased Nrf2 nuclear translocation and HO-1 expression, which were suppressed by Nrf2 knockdown in HG/ox-LDL-treated endothelial cells. H_2S increased S-sulfhydration of Keap1, induced Nrf2 dissociation from Keap1, enhanced Nrf2 nuclear translocation, and inhibited O_2~- generation, which were abrogated after Keap1 mutated at Cys151, but not Cys273, in endothelial cells. Collectively, H_2S attenuates diabetes-accelerated atherosclerosis, which may be related to inhibition of oxidative stress via Keap1 sulfhy-drylation at Cys151 to activate Nrf2 signaling. This may provide a novel therapeutic target to prevent atherosclerosis in the context of diabetes.
机译:硫化氢(H_2S)具有强大的抗氧化和抗炎特性,可调节多种心血管功能。然而,其在糖尿病加速的动脉粥样硬化中的确切作用仍不清楚。我们在这里报告说,H_2S减少了主链动脉粥样硬化斑块的形成,减少了超氧化物(O_2〜-)的产生和链脲佐菌素(STZ)诱导的LDLr〜(-/-)小鼠的黏附分子,但在LDLr〜(-/-却没有) Nrf2〜(-/-)小鼠。在体外,H_2S抑制了泡沫细胞的形成,减少了O_2〜-的产生,并增加了核因子红系2相关因子2(Nrf2)的核转录,从而导致高糖(HG)中血红素加氧酶1(HO-1)表达上调。加上氧化型LDL(ox-LDL)处理的野生型原发性腹膜巨噬细胞,而非Nrf2〜(-/-)小鼠。 H_2S还降低了O_2〜-和粘附分子水平,并增加了Nrf2核易位和HO-1表达,这在HG / ox-LDL处理的内皮细胞中被Nrf2抑制了。 H_2S增加了Keap1的S硫酸盐化,诱导了Nrf2从Keap1的解离,增强了Nrf2的核易位,并抑制了O_2〜-的生成,Keap1在Cys151突变但在Cys273突变后废除了。总的来说,H_2S可减轻糖尿病加速的动脉粥样硬化,这可能与通过Cys151处的Keap1巯基干燥作用激活Nrf2信号传导而抑制氧化应激有关。这可以提供预防糖尿病背景下的动脉粥样硬化的新颖治疗靶标。

著录项

  • 来源
    《Diabetes》 |2016年第10期|3171-3184|共14页
  • 作者单位

    Department of Cardiology, The First Affiliated Hospital of Xiamen University, Xiamen, China,Collaborative Innovation Center for Cardiovascular Disease Translatonal Medicine, Atherosclerosis Research Centre, Nanjing Medical University, Nanjing, China;

    Collaborative Innovation Center for Cardiovascular Disease Translatonal Medicine, Atherosclerosis Research Centre, Nanjing Medical University, Nanjing, China;

    Collaborative Innovation Center for Cardiovascular Disease Translatonal Medicine, Atherosclerosis Research Centre, Nanjing Medical University, Nanjing, China;

    Collaborative Innovation Center for Cardiovascular Disease Translatonal Medicine, Atherosclerosis Research Centre, Nanjing Medical University, Nanjing, China;

    Collaborative Innovation Center for Cardiovascular Disease Translatonal Medicine, Atherosclerosis Research Centre, Nanjing Medical University, Nanjing, China;

    Collaborative Innovation Center for Cardiovascular Disease Translatonal Medicine, Atherosclerosis Research Centre, Nanjing Medical University, Nanjing, China;

    Collaborative Innovation Center for Cardiovascular Disease Translatonal Medicine, Atherosclerosis Research Centre, Nanjing Medical University, Nanjing, China;

    Department of Geriatrics, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China;

    Institute of Cardiovascular Sciences and Key Laboratory of Molecular Cardiovascular Sciences, Ministry of Education, Peking University Health Science Center, Beijing, China;

    Institute of Cardiovascular Sciences and Key Laboratory of Molecular Cardiovascular Sciences, Ministry of Education, Peking University Health Science Center, Beijing, China;

    Department of Pharmacology, National University of Singapore, Singapore, Singapore;

    Faculty of Life Sciences, The University of Manchester, Manchester, U.K.;

    Center for Metabolic Disease Research, Department of Pharmacology, Temple University School of Medicine, Philadelphia, PA;

    The Third Affiliated Hospital of Harbin Medical University, Institute of Metabolic Disease, Heilongjiang Academy of Medical Science, Harbin, China;

    Institute for Nutritional Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai, China;

    Department of Clinical Pharmacology, Cardiovascular Division, British Heart Foundation Centre of Research Excellence, King's College London, London, U.K.;

    Department of Cardiology, The First Affiliated Hospital of Xiamen University, Xiamen, China;

    Collaborative Innovation Center for Cardiovascular Disease Translatonal Medicine, Atherosclerosis Research Centre, Nanjing Medical University, Nanjing, China;

  • 收录信息 美国《科学引文索引》(SCI);美国《化学文摘》(CA);
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

  • 入库时间 2022-08-18 03:46:10

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号